MAP2K7 and Hypertension: This has been manifested in the wide variation of some event rates (eg, hypertension was not reported in the Larkin et al19 study compared with 15% all-grade hypertension and 12% high-grade hypertension in the Flaherty et al study).16 Subgroup analysis has been conducted to overcome this issue and to provide deeper understanding of the differences between individual MEK inhibitors in different CV risks.